Dr. Kalsi brings more than 20 years of experience in global clinical development, medical affairs, investment strategy, and regulatory affairs to Asklepion Pharmaceuticals, LLC. Most recently, Dr. Kalsi served as the SVP/CMO of Tissue Gene, where he headed medical, clinical, and regulatory development functions in cell and gene therapeutics and helped IPO its lead asset in Knee OA on the KOSDAQ. Prior to his time with Tissue Gene, Dr. Kalsi served as Corporate Vice President for Clinical Development & Medical Affairs at Emergent BioSolutions Inc. At MDS Pharma, he was the head of Medical Affairs and Regulatory Affairs.
Dr. Kalsi held executive leadership positions with ICON plc in clinical development and medical affairs. He began his pharmaceutical career at Lundbeck A/S in Copenhagen, Denmark. Dr. Kalsi received his medical degrees in surgery and medicine from Glancy Medical College (GMC), followed by postgraduate training courses in public health medicine at St George’s Hospital in London and Pharmaceutical Medicine postgraduate training at Cardiff University, UK. He is a member of the British Association of Pharmaceutical Physicians and Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians.